Peng Z*, Zhang X, Liang H, Zheng Z, Wang Z, Liu H, Hu J, Sun Y, Zhang Y, Yan H, Tong L, Xu J, Ji J, Shen L*. Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.,JAMA Oncology,2025;11(6):619-624.

Qi C#, Liu C#, Peng Z#, Zhang Y#, Wei J#, Qiu W#, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L*. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.,Lancet,2025;405(10494):2049-2060.

Cheng S, Han Z, Dai D, Li F, Zhang X, Lu M, Lu Z, Wang X, Zhou J, Li J, Guo X, Song P, Qiu C, Shen W, Zhang Q, Zhu N, Wang X, Tan Y, Kou Y, Yin X, Shen L, Peng Z. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy.,Cell Rep Med,2024 Jan 16;5(1):101355.

Peng Z#, Wei J#, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y*, Shen L*. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.,Clinical Cancer Research,27(11):3069-3078.

Peng Z#, Cheng S#, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y, Shen L*. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.,Cancer Immunology Research,8(10):1251-1261.

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study,Cancer Commun (Lond),41(11):1173-1182

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.,J Immunother Cancer,2022 Mar;10(3)

Han Z, Cheng S, Dai D, Kou Y, Zhang X, Li F, Yin X, Ji J, Zhang Z, Wang X, Zhu N, Zhang Q, Tan Y, Guo X, Shen L, Peng Z. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.,Clin Transl Med,2023 Jul;13(7):e1312.

Peng Z*, Chen P, Lu J, Wan Y, Zheng Y, Ye F, Yang J, Liu Y, Pan H, Sun M, Fan Q, Yuan Y, Chen K, Sun Z, Tian H, Xia Y, Shen L*. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial.,EClinicalMedicine,

Xie T, Zhang Z, Qi C, Lu M, Zhang X, Li J, Shen L, Peng Z. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.,Oncologist,doi: 10.1002/onco.13940.

Song P, Peng Z*, Guo X*. Gut microbial metabolites in cancer therapy. Trends Endocrinol Metab.,Trends in Endocrinology & Metabolism,

图说肿瘤免疫治疗, 参编, 人民卫生出版社, 2021.9

食管癌胃癌临床实践研究与解析, 参编, 江苏凤凰科学技术出版社, 2022.4

万人计划青年拔尖人才项目, 万人计划青年拔尖人才项目, 第1完成人, 中组部, 2022.10

北京市“高创计划·登峰”项目, 北京市“高创计划·登峰”项目, 第1完成人, 北京市卫生健康委员会, 2025.8

青年科学家奖, 青年科学家奖, 第1完成人, 中国抗癌协会, 2023.11

消化道肿瘤精准治疗与转化研究, 中国抗癌协会科技奖一等奖, 第5完成人, 中国抗癌协会, 2025.8

一株粘膜粘液乳杆菌及其在制备治疗癌症的药物中的应用, 发明专利, 第5完成人, 中华人民共和国国家知识产权局, 中国, 2025.6

恶性肿瘤群体基因组变异检测理论与技术, 参加者, 2024.1.1～2028.12.31, 国家自然科学基金重点项目

肠道菌群代谢产物牛磺胆酸调控CCL5促进CD8+T细胞浸润增敏MSI-H胃癌 抗PD-1治疗的机制研究, 课题负责人, 2023.1.1～2026.12.31, 国家自然科学基金

免疫治疗EB病毒感染相关胃癌免疫微环境动态改变及耐药机制研究, 课题负责人, 2024.10.1～2027.9.30, 北京市自然科学基金

肠道菌群调控胃肠肿瘤免疫治疗疗效的免疫机制研究, 课题负责人, 2021.10.12～2024.10.15, 北京市自然科学基金重点研究专题项目

EBV相关胃癌免疫微环境特征及其在评估免疫治疗疗效中的作用, 课题负责人, 2021.1.1～2021.12.31, 北京大学

DNA甲基化在EBV相关胃癌免疫治疗疗效评估中的作用及机制研究, 课题负责人, 2022.1.1～2022.12.31, 北京大学

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2026	肿瘤内科学	博士	专业学位	临床技能训练与研究	申请考核制
2026	肿瘤学	博士	学术学位	胃癌的分子分型和精准治疗	申请考核制
2026	肿瘤学	直博	学术学位	（肿瘤免疫）胃癌的分子分型和精准治疗	推荐免试
2026	肿瘤学	硕士	学术学位	胃癌的分子分型和精准治疗	推荐免试